[1] Aarsland, D., Andersen, K., Larsen, J.P., Lolk, A. and Kragh-Sorensen, P. (2003) Prevalence and Characteristics of Dementia in Parkinson Disease: An 8-Year Prospective Study. Archives of Neurology, 60, 387-392. http://dx.doi.org/10.1001/archneur.60.3.387
[2] Cummings, J.L. (1988) Intellectual Impairment in Parkinson’s Disease: Clinical, Pathologic, and Biochemical Correlates. Journal of Geriatric Psychiatry and Neurology, 1, 24-36.
http://dx.doi.org/10.1177/089198878800100106
[3] Giladi, N., Treves, T.A., Paleacu, D., Shabtai, H., Orlov, Y., Kandinov, B., et al. (2000) Risk Factors for Dementia, Depression and Psychosis in Long-Standing Parkinson’s Disease. Journal of Neural Transmission, 107, 59-71. http://dx.doi.org/10.1007/s007020050005
[4] Hobson, P. and Meara, J. (2004) Risk and Incidence of Dementia in a Cohort of Older Subjects with Parkinson’s Disease in the United Kingdom. Movement Disorders, 19, 1043-1049.
http://dx.doi.org/10.1002/mds.20216
[5] Bublak, P., Muller, U., Gron, G., Reuter, M. and von Cramon, D.Y. (2002) Manipulation of Working Memory Information Is Impaired in Parkinson’s Disease and Related to Working Memory Capacity. Neuropsychology, 16, 577-590. http://dx.doi.org/10.1037/0894-4105.16.4.577
[6] Muslimovic, D., Post, B., Speelman, J.D. and Schmand, B. (2005) Cognitive Profile of Patients with Newly Diagnosed Parkinson Disease. Neurology, 65, 1239-1245.
http://dx.doi.org/10.1212/01.wnl.0000180516.69442.95
[7] Montse, A., Pere, V., Carme, J., Francesc, V. and Eduardo, T. (2001) Visuospatial Deficits in Parkinson’s Disease Assessed by Judgment of Line Orientation Test: Error Analyses and Practice Effects. Journal of Clinical and Experimental Neuropsychology, 23, 592-598. http://dx.doi.org/10.1076/jcen.23.5.592.1248
[8] Emre, M., Aarsland, D., Brown, R., Burn, D.J., Duyckaerts, C., Mizuno, Y., et al. (2007) Clinical Diagnostic Criteria for Dementia Associated with Parkinson’s Disease. Movement Disorders, 22, 1689-1707. http://dx.doi.org/10.1002/mds.21507
[9] Aarsland, D., Larsen, J.P., Karlsen, K., Lim, N.G. and Tandberg, E. (1999) Mental Symptoms in Parkinson’s Disease Are Important Contributors to Caregiver Distress. International Journal of Geriatric Psychiatry, 14, 866-874.
http://dx.doi.org/10.1002/(SICI)1099-1166(199910)14:10<866::AID-GPS38>3.0.CO;2-Z
[10] Schrag, A., Jahanshahi, M. and Quinn, N. (2000) How Does Parkinson’s Disease Affect Quality of Life? A Comparison with Quality of Life in the General Population. Movement Disorders, 15, 1112-1118.
http://dx.doi.org/10.1002/1531-8257(200011)15:6<1112::AID-MDS1008>3.0.CO;2-A
[11] Braak, H., Del, T.K., Rub, U., de Vos, R.A., Jansen Steur, E.N. and Braak, E. (2003) Staging of Brain Pathology Related to Sporadic Parkinson’s Disease. Neurobiology of Aging, 24, 197-211.
http://dx.doi.org/10.1016/S0197-4580(02)00065-9
[12] Rektorova, I., Srovnalova, H., Kubikova, R. and Prasek, J. (2008) Striatal Dopamine Transporter Imaging Correlates with Depressive Symptoms and Tower of London Task Performance in Parkinson’s Disease. Movement Disorders, 23, 1580-1587. http://dx.doi.org/10.1002/mds.22158
[13] Dickson, D.W., Fujishiro, H., Orr, C., DelleDonne, A., Josephs, K.A., Frigerio, R., et al. (2009) Neuropathology of Non-Motor Features of Parkinson Disease. Parkinsonism & Related Disorders, 15, S1-S5. http://dx.doi.org/10.1016/S1353-8020(09)70769-2
[14] Emre, M., Aarsland, D., Albanese, A., Byrne, E.J., Deuschl, G., De Deyn, P.P., et al. (2004) Rivastigmine for Dementia Associated with Parkinson’s Disease. New England Journal of Medicine, 351, 2509-2518. http://dx.doi.org/10.1056/NEJMoa041470
[15] Oertel, W., Poewe, W., Wolters, E., De Deyn, P.P., Emre, M., Kirsch, C., et al. (2008) Effects of Rivastigmine on Tremor and Other Motor Symptoms in Patients with Parkinson’s Disease Dementia: A Retrospective Analysis of a Double-Blind Trial and an Open-Label Extension. Drug Safety, 31, 79-94.
http://dx.doi.org/10.2165/00002018-200831010-00007
[16] Jadad, A.R., Moore, R.A., Carroll, D., Jenkinson, C., Reynolds, D.J., Gavaghan, D.J., et al. (1996) Assessing the Quality of Reports of Randomized Clinical Trials: Is Blinding Necessary? Controlled Clinical Trials, 17, 1-12. http://dx.doi.org/10.1016/0197-2456(95)00134-4
[17] Cohen, J. (1988) Statistical Power Analysis for the Behavioral Sciences. 2nd Edition, Lawrence Erlbaum Associates, Hillsdale.
[18] Ravina, B., Putt, M., Siderowf, A., Farrar, J.T., Gillespie, M., Crawley, A., et al. (2005) Donepezil for Dementia in Parkinson’s Disease: A Randomised, Double Blind, Placebo Controlled, Crossover Study. Journal of Neurology, Neurosurgery & Psychiatry, 76, 934-939.
http://dx.doi.org/10.1136/jnnp.2004.050682
[19] Leroi, I., Brandt, J., Reich, S.G., Lyketsos, C.G., Grill, S., Thompson, R., et al. (2004) Randomized Placebo-Controlled Trial of Donepezil in Cognitive Impairment in Parkinson’s Disease. International Journal of Geriatric Psychiatry, 19, 1-8. http://dx.doi.org/10.1002/gps.993
[20] Aarsland, D., Laake, K., Larsen, J.P. and Janvin, C. (2002) Donepezil for Cognitive Impairment in Parkinson’s Disease: A Randomised Controlled Study. Journal of Neurology, Neurosurgery & Psychiatry, 72, 708-712. http://dx.doi.org/10.1136/jnnp.72.6.708
[21] Dubois, B., Tolosa, E., Katzenschlager, R., Emre, M., Lees, A.J., et al. (2012) Donepezil in Parkinson’s Disease Dementia: A Randomized, Double-Blind Efficacy and Safety Study. Movement Disorders, 27, 1230-1238. http://dx.doi.org/10.1002/mds.25098
[22] Litvinenko, I.V., Odinak, M.M., Mogil’naya, V.I. and Emelin, A.Y. (2008) Efficacy and Safety of Galantamine (Reminyl) for Dementia in Patients with Parkinson’s Disease (An Open Controlled Trial). Neuroscience and Behavioral Physiology, 38, 937-945. http://dx.doi.org/10.1007/s11055-008-9077-3
[23] Poewe, W., Wolters, E., Emre, M., Onofrj, M., Hsu, C., Tekin, S., et al. (2006) Long-Term Benefits of Rivastigmine in Dementia Associated with Parkinson’s Disease: An Active Treatment Extension Study. Movement Disorders, 21, 456- 461. http://dx.doi.org/10.1002/mds.20700
[24] Aarsland, D., Hutchinson, M. and Larsen, J.P. (2003) Cognitive, Psychiatric and Motor Response to Galantamine in Parkinson’s Disease with Dementia. International Journal of Geriatric Psychiatry, 18, 937-941. http://dx.doi.org/10.1002/gps.949
[25] Minett, T.S., Thomas, A., Wilkinson, L.M., Daniel, S.L., Sanders, J., Richardson, J., et al. (2003) What Happens When Donepezil Is Suddenly Withdrawn? An Open Label Trial in Dementia with Lewy Bodies and Parkinson’s Disease with Dementia. International Journal of Geriatric Psychiatry, 18, 988-993.
http://dx.doi.org/10.1002/gps.995
[26] Tombaugh, T.N. and McIntyre, N.J. (1992) The Mini-Mental State Examination: A Comprehensive Review. Journal of the American Geriatrics Society, 40, 922-935.
http://dx.doi.org/10.1111/j.1532-5415.1992.tb01992.x
[27] Crum, R.M., Anthony, J.C., Bassett, S.S. and Folstein, M.F. (1993) Population-Based Norms for the Mini-Mental State Examination by Age and Educational Level. The Journal of the American Medical Association, 269, 2386-2391. http://dx.doi.org/10.1001/jama.1993.03500180078038